Kinase inhibitors: Vice becomes virtue

Slides:

Advertisements

Similar presentations

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Advertisements

Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells Nilay Sethi, Xudong Dai, Christopher.

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

by Rogelio Zamilpa, and Merry L. Lindsey

The Kinase-Independent, Second Life of CDK6 in Transcription

Connecting COX-2 and Wnt in cancer

RAS and ROS—A Story of Pseudomonas Survival

IRS-1: Auditing the effectiveness of mTOR inhibitors

All roads lead to FoxO Cell Metabolism

Wild-Type RAS: Keeping Mutant RAS in CHK

HER2/HER3 heterodimers in prostate cancer

Volume 14, Issue 2, Pages (August 2008)

Volume 11, Issue 4, Pages (April 2007)

The Akt-mTOR tango and its relevance to cancer

RAS unplugged: Negative feedback and oncogene-induced senescence

Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway Gozde Akgumus, Fengqi.

Killing Tumors by Keeping Ras and PI3′ Kinase Apart

A Flt3L Encounter: mTOR Signaling in Dendritic Cells

mTORC1: Turning Off Is Just as Important as Turning On

Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD

Volume 13, Issue 1, Pages 1-2 (January 2008)

Figure 1 mTOR complex biology

Volume 92, Issue 5, Pages (March 1998)

A Radical Role for p38 MAPK in Tumor Initiation

CALming Down T Cell Acute Leukemia

Volume 29, Issue 3, Pages (March 2016)

The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Identification of TOR Signaling Complexes

Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers Yu Chen, Charles L. Sawyers Cancer Cell Volume.

PTEN Enters the Nuclear Age

The CAMplexities of Central Ghrelin

Volume 22, Issue 6, Pages (December 2012)

Volume 46, Issue 5, Pages (June 2012)

Rapamycin: One Drug, Many Effects

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Volume 20, Issue 1, Pages 3-5 (July 2011)

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

FGFR Signaling as a Target for Lung Cancer Therapy

Characterizing the Killer Colorectal Carcinomas

IRS-1: Auditing the effectiveness of mTOR inhibitors

mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells

The RAF Inhibitor Paradox Revisited

Volume 139, Issue 2, Pages e3 (August 2010)

NOTCH and PI3K-AKT Pathways Intertwined

AKT/PKB Signaling: Navigating Downstream

Ophélie Meynet, Jean-Ehrland Ricci Trends in Molecular Medicine

Rapamycin: One Drug, Many Effects

aSIRTing Control over Cancer Stem Cells

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

Volume 14, Issue 4, Pages (October 2008)

mTOR and Akt Signaling in Cancer: SGK Cycles In

Alex Kentsis, A. Thomas Look Cell Stem Cell

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Smoothing Out Drug Resistance

Brian K. Kennedy, Dudley W. Lamming Cell Metabolism

Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn Kidney International

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing Richard A.F. Clark,

Glycogen Synthase Kinase-3 and Cancer: Good Cop, Bad Cop?

Nutrient Sensing, Metabolism, and Cell Growth Control

Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Ibrutinib Treatment of CLL: The Cancer Fights Back

Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX Jean-Christophe Marine Cancer Cell Volume.

Volume 12, Issue 6, Pages (December 2007)

PTEN and p53: Who will get the upper hand?

Turning Reciprocal Feedback Regulation into Combination Therapy

Skp2, the FoxO1 hunter Cancer Cell

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome

Presentation transcript:

Kinase inhibitors: Vice becomes virtue Peter K. Vogt, Sohye Kang Cancer Cell Volume 9, Issue 5, Pages 327-328 (May 2006) DOI: 10.1016/j.ccr.2006.05.002 Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 1 Compound PI-103 inhibits PI3K and TOR This target combination is essential for the ability of PI-103 to arrest the growth of glioma cells and may reflect the need to interfere with both the forward signal from PI3K and the negative feedback from TOR for an effective shutdown of the signaling chain. As indicated by the question marks, there is still uncertainty about the precise upstream targets and their relative importance for the negative feedback loop. IRS, insulin receptor substrate; PI3K, phosphoinositide 3 kinase; AKT, serine-threonine kinase Akt; TSC, tuberous sclerosis complex; RHEB, Ras homolog enriched in brain; TOR, target of rapamycin; S6K, S6 protein kinase. Cancer Cell 2006 9, 327-328DOI: (10.1016/j.ccr.2006.05.002) Copyright © 2006 Elsevier Inc. Terms and Conditions